Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...

A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and ...

The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 (an autologous CAR T-cell product ...

Harpreet Singh, MD, former director of the FDA's Division of Oncology 2 and chief medical officer of Precision for Medicine, discusses the FDA's draft guidance on the use of overall survival (OS) as ...

CORTLAND, Ohio (MyValleyTributes) – Carolyn Roman, 72, of Cortland passed away peacefully on Sunday morning, October 5, 2025 with her family by her side after complications stemming from a short, but ...

Recognition highlights commercial potential of Telo’s telomere-based MRD technology in the growing precision oncology market Toronto, Ontario–(Newsfile Corp. – October 9, 2025) – Telo Genomics Corp.

The former Chief Medical Officer was brought to tears on the TV show Keys To My Life when he went back to the apartment he ...

Marciniak has shared publicly his struggles with health in the past. In 2009, while serving at Bay City Central High School, ...

REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.

From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.

The AACR Cancer Progress Report 2025 highlights recent advances in cancer research, emphasizing the importance of federal funding.